Table 1.
Baseline characteristics of the study population according to the MHR tertiles.
| Variables | T1: < 7.7 | T2: 7.7–11.3 | T3: > 11.3 | P -value |
|---|---|---|---|---|
| MHR | 5.9 (4.9–6.9) | 9.3 (8.5–10.2) | 14.1 (12.4–16.7) | <0.001 |
| Age (years) | 61 ± 9 | 60 ± 10 | 58 ± 11 | <0.001 |
| Male sex, n (%) | 355 (62.7) | 449 (77.4) | 515 (89.7) | <0.001 |
| BMI (kg/m2) | 25.2 ± 2.9 | 25.7 ± 3.1 | 26.2 ± 3.1 | <0.001 |
| SBP (mmHg) | 132 ± 16 | 131 ± 16 | 127 ± 17 | <0.001 |
| DBP (mmHg) | 77 ± 11 | 77 ± 10 | 75 ± 11 | 0.001 |
| Risk factors | ||||
| Smoking, n (%) | 156 (27.6) | 250 (43.1) | 354 (61.7) | <0.001 |
| Hypertension, n (%) | 373 (65.9) | 364 (62.8) | 358 (62.4) | 0.397 |
| Diabetes, n (%) | 246 (43.5) | 303 (52.5) | 241 (42.0) | 0.001 |
| Dyslipidemia, n (%) | 379 (67.0) | 468 (80.7) | 528 (92.0) | <0.001 |
| Previous MI, n (%) | 88 (15.5) | 110 (19.0) | 132 (23.0) | 0.006 |
| Previous PCI, n (%) | 109 (19.3) | 118 (20.3) | 114 (19.9) | 0.899 |
| Previous CVA, n (%) | 26 (4.6) | 34 (5.9) | 40 (7.0) | 0.230 |
| CKD, n (%) | 12 (2.1) | 13 (2.2) | 24 (4.2) | 0.063 |
| PAD, n (%) | 43 (7.6) | 66 (11.4) | 67 (11.7) | 0.041 |
| Heart failure, n (%) | 28 (4.9) | 37 (6.4) | 55 (9.6) | 0.007 |
| LVEF (%) | 65 (61–68) | 65 (60–68) | 63 (58–67) | <0.001 |
| Clinical presentation | ||||
| UA, n (%) | 482 (85.2) | 439 (75.7) | 355 (61.8) | <0.001 |
| NSTEMI, n (%) | 56 (9.9) | 78 (13.4) | 86 (15.0) | 0.031 |
| STEMI, n (%) | 28 (4.9) | 63 (10.9) | 133 (23.2) | <0.001 |
| GRACE risk score | 92 (73–110) | 92 (77–123) | 104 (77–144) | <0.001 |
| Laboratory results | ||||
| Monocyte count (× 106/μl) | 260 (210–300) | 360 (320–408) | 500 (430–590) | <0.001 |
| Neutrophil count (× 106/μl) | 3,365 (2,770–4,173) | 3,970 (3,253–4,780) | 4,670 (3,860–5,663) | <0.001 |
| Lymphocyte count (× 106/μl) | 1,575 (1,328–1,903) | 1,780 (1,440–2,190) | 1,920 (1,540–2,380) | <0.001 |
| NLR | 2.1 (1.6–2.9) | 2.3 (1.8–2.9) | 2.4 (1.8–3.3) | <0.001 |
| hs-CRP (mg/L) | 0.88 (0.42–1.84) | 1.46 (0.71–3.38) | 2.29 (0.91–6.43) | <0.001 |
| Total cholesterol (mg/dl) | 166.0 ± 38.8 | 160.2 ± 36.9 | 154.8 ± 38.3 | <0.001 |
| LDL-C (mg/dl) | 96.3 ± 33.2 | 94.1 ± 30.7 | 92.8 ± 30.0 | 0.165 |
| HDL-C (mg/dl) | 46.4 ± 8.7 | 39.2 ± 7.3 | 34.3 ± 6.7 | <0.001 |
| Triglycerides (mg/dl) | 106.3 (78.8–151.5) | 136.0 (95.7–192.9) | 143.9 (105.2 ± 200.4) | <0.001 |
| FPG (mg/dl) | 111.6 ± 29.1 | 116.3 ± 32.0 | 115.1 ± 31.8 | 0.027 |
| Glycosylated hemoglobin (%) | 5.9 (5.5–6.9) | 6.3 (5.6–7.3) | 6.1 (5.6–7.2) | <0.001 |
| cTnI (ng/ml) | 0.00 (0.00–0.01) | 0.00 (0.00–0.01) | 0.01 (0.00–0.10) | <0.001 |
| Admission medical therapy | ||||
| Aspirin, n (%) | 395 (69.8) | 435 (75.0) | 432 (75.3) | 0.062 |
| P2Y12 inhibitors, n (%) | 193 (34.1) | 255 (44.0) | 253 (44.1) | <0.001 |
| Statins, n (%) | 384 (67.8) | 426 (73.4) | 428 (74.6) | 0.026 |
| ACEI/ARBs, n (%) | 161 (28.4) | 175 (30.2) | 155 (27.0) | 0.491 |
| β-blockers, n (%) | 190 (33.6) | 212 (36.6) | 237 (41.3) | 0.025 |
| Angiographic findings | ||||
| Left-main and/or multivessel disease, n (%) | 469 (82.9) | 480 (82.8) | 509 (88.7) | 0.006 |
| Chronic total occlusion, n (%) | 105 (18.6) | 116 (20.0) | 142 (24.7) | 0.027 |
| Lesions with length >20 mm, n (%) | 294 (51.9) | 295 (50.9) | 313 (54.5) | 0.440 |
| Bifurcation or trifurcation lesions, n (%) | 434 (76.7) | 434 (74.8) | 430 (74.9) | 0.715 |
| SYNTAX score | 19 (12–27) | 20 (13–27) | 22 (14–31) | <0.001 |
| Procedural results | ||||
| Target vessel-LM, n (%) | 19 (3.4) | 18 (3.1) | 20 (3.5) | 0.935 |
| Target vessel-LAD, n (%) | 129 (22.8) | 142 (24.5) | 124 (21.6) | 0.505 |
| Target vessel-LCX, n (%) | 71 (12.5) | 85 (14.7) | 67 (11.7) | 0.300 |
| Target vessel-RCA, n (%) | 105 (18.6) | 122 (21.0) | 96 (16.7) | 0.170 |
| Complete revascularization, n (%) | 377 (66.6) | 378 (65.2) | 302 (52.6) | <0.001 |
| Prescription at discharge | ||||
| Aspirin, n (%) | 564 (99.6) | 574 (99.0) | 566 (98.6) | 0.178 |
| Clopidogrel, n (%) | 518 (91.5) | 536 (92.4) | 525 (91.5) | 0.804 |
| Ticagrelor, n (%) | 48 (8.5) | 44 (7.6) | 49 (8.5) | 0.804 |
| Statins, n (%) | 566 (100.0) | 580 (100.0) | 574 (100.0) | NA |
| ACEI/ARBs, n (%) | 253 (44.7) | 278 (47.9) | 297 (51.7) | 0.059 |
| β-blockers, n (%) | 373 (65.9) | 397 (68.4) | 441 (76.8) | <0.001 |
MHR, monocyte to HDL-C ratio; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CVA, cerebrovascular accident; PAD, peripheral artery disease; LVEF, left ventricular ejection fraction; CKD, chronic kidney disease; UA, unstable angina; NSTEMI, non ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; GRACE, Global registry of acute coronary events; NLR, neutrophil to lymphocyte ratio; hs-CRP, high sensitive C-reactive protein; LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; FPG, fasting plasma glucose; cTnI, cardiac troponin I; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; SYNTAX, Synergy between PCI with TAXUS and Cardiac Surgery; LM, left main artery; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.